2021年中国慢性髓性白血病患者关注的问题调查与分析

OBJECTIVE: To investigate the concerns of adult patients with chronic myeloid leukemia（CML）in the chronic phase receiving tyrosine kinase inhibitor（TKI）therapy in China. METHODS: A cross-sectional questionnaire including 23 issues of concern was filled by patients with CML nationwide from August to September 2021. The results were compared with those from 2015 to 2016. RESULTS: Data from 952 questionnaires were analyzed. The five most concerned issues were “TKI-related adverse effects and management”（66％）, “stopping TKI therapy”（46％）, “CML risk assessment”（46％）, “TKI dose reduction”（42％）, and “restrictions in daily life activities”（41％）. Compared with the results from 2015 to 2016, patients paid more attention to “TKI-related adverse effects and management”, “monitoring”, and “interpretation of laboratory reports”（all P<0.01）. Concerns of “TKI reimbursement policies”,“price reduction of TKIs”, and issues related to generic TKIs decreased significantly（all P<0.01）. Multivariate analysis showed that female patients（OR＝1.8, 95％ CI 1.4–2.5, P<0.001）, elderly patients（OR＝1.0, 95％ CI 1.0–1.0, P<0.001）, or patients with bachelor's degree or higher（OR＝1.8, 95％ CI 1.3–2.4, P<0.001）were more concerned with “TKI dose reduction” than others. Patients with a bachelor's degree or higher（OR＝1.6, 95％ CI 1.2–2.2, P＝0.002）paid more attention to “CML risk assessment”, whereas those currently receiving a second- or third-generation TKI therapy（OR＝1.9, 95％ CI 1.3–2.6, P<0.001）were more concerned about “TKI resistance”. CONCLUSION: Patients with CML paid the most attention to “TKI-related adverse effects and management”, “stopping TKI therapy”, “CML risk assessment”, “TKI dose reduction”, and “restrictions in daily life activities”. Patients' sociodemographic covariates and treatment status were associated with their concerns.